Find therapies in clinical trials near you – page 16

Pembrolizumab for Patients with Localised dMMR Colon Cancer: Neoadjuvant and Organ-Sparing Treatment Study

Pembrolizumab for Patients with Localised dMMR Colon Cancer: Neoadjuvant and Organ-Sparing Treatment Study

A study of pembrolizumab, belzutifan, and lenvatinib before main treatment in patients with localized kidney cancer

A study of pembrolizumab, belzutifan, and lenvatinib before main treatment in patients with localized kidney cancer

Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease

Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Study of Drug Combination with Pembrolizumab Guided by Blood Biomarkers for Patients with Metastatic Non-Small Cell Lung Cancer

Study of Drug Combination with Pembrolizumab Guided by Blood Biomarkers for Patients with Metastatic Non-Small Cell Lung Cancer

A study of pembrolizumab and lenvatinib for patients with high risk locally advanced cervical cancer after chemoradiotherapy and brachytherapy

A study of pembrolizumab and lenvatinib for patients with high risk locally advanced cervical cancer after chemoradiotherapy and brachytherapy

Testing UCPVax vaccine with or without pembrolizumab and temozolomide in patients with unmethylated MGMT glioblastoma after initial treatment

Testing UCPVax vaccine with or without pembrolizumab and temozolomide in patients with unmethylated MGMT glioblastoma after initial treatment

Study of MIDRIX-LUNG immunotherapy combined with anti-PD-1 treatment in patients with metastatic non-small-cell lung cancer

Study of MIDRIX-LUNG immunotherapy combined with anti-PD-1 treatment in patients with metastatic non-small-cell lung cancer

Evaluating shorter duration of pembrolizumab and pemetrexed treatment in patients with metastatic non-small cell lung cancer who have not progressed after 6 months

Evaluating shorter duration of pembrolizumab and pemetrexed treatment in patients with metastatic non-small cell lung cancer who have not progressed after 6 months

Study of Pembrolizumab for Patients with Stage IIb/c Melanoma

Study of Pembrolizumab for Patients with Stage IIb/c Melanoma

Study of Pembrolizumab for Patients with High-Risk Stage IIB/IIC Melanoma

Study of Pembrolizumab for Patients with High-Risk Stage IIB/IIC Melanoma

Study of IOMX-0675 alone or combined with pembrolizumab for patients with previously treated advanced or metastatic solid tumors